Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in Moderate to Severe Plaque Psoriasis
NCT00287118Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2004
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Primary endpoint: Percentage of Subjects With Physician's Global Assessment (PGA) Ratings of 'Excellent' or 'Cleared' at Week 24. Started Oct 2004; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00287118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287118.